Published in Hepatitis Weekly, November 17th, 2003
According to a study from Saudi Arabia, "hepatitis C virus (HCV) infection is the most common cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma worldwide. Recombinant interferon alpha (IFN-alpha) is currently the recommended therapy for patients with HCV-induced chronic liver disease. A flu-like syndrome and depression are the most common side effects of IFN-alpha therapy."
"Severe renal adverse effects-including nephrotic syndrome and acute renal failure-are, fortunately, rare, but may be life-threatening; these are often reversible following prompt...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.